PubMed=26937552; DOI=10.1089/mab.2015.0077
Yukinari Kato, Satoshi Ogasawara, Hiroharu Oki, Ryusuke Honma, Michiaki Takagi, Yuki Fujii, Takuro Nakamura, Noriko Saidoh, Hazuki Kanno, Mitsuo Umetsu, Satoshi Kamata ...Show all 18 authors... , Hiroshi Kubo, Mitsuhiro Yamada, Yoshihiko Sawa, Kei-ichi Morita, Hiroyuki Harada, Hiroyoshi Suzuki, Mika Kato Kaneko; Show fewer authors
Novel monoclonal antibody LpMab-17 developed by CasMab technology distinguishes human podoplanin from monkey podoplanin.
Monoclon. Antib. Immunodiagn. Immunother. 35:109-116(2016)

PubMed=27031228; DOI=10.1371/journal.pone.0152912; PMCID=PMC4816300
Yukinari Kato, Satoshi Ogasawara, Hiroharu Oki, Polina Goichberg, Ryusuke Honma, Yuki Fujii, Mika Kato Kaneko;
LpMab-12 established by CasMab technology specifically detects sialylated O-glycan on Thr52 of platelet aggregation-stimulating domain of human podoplanin.
PLoS ONE 11:e0152912.1-e0152912.13(2016)

PubMed=27328060; DOI=10.1089/mab.2016.0006
Satoshi Ogasawara, Mika Kato Kaneko, Ryusuke Honma, Hiroharu Oki, Yuki Fujii, Michiaki Takagi, Hiroyoshi Suzuki, Yukinari Kato;
Establishment of mouse monoclonal antibody LpMab-13 against human podoplanin.
Monoclon. Antib. Immunodiagn. Immunother. 35:155-162(2016)

PubMed=27564251; DOI=10.1089/mab.2016.0031
Satoshi Ogasawara, Mika Kato Kaneko, Yukinari Kato;
LpMab-19 recognizes sialylated O-Glycan on Thr76 of human podoplanin.
Monoclon. Antib. Immunodiagn. Immunother. 35:245-253(2016)

PubMed=28101903; DOI=10.1002/cam4.954; PMCID=PMC5313638
Mika Kato Kaneko, Takuro Nakamura, Ryusuke Honma, Satoshi Ogasawara, Yuki Fujii, Shinji Abe, Michiaki Takagi, Hiroyuki Harada, Hiroyoshi Suzuki, Yasuhiko Nishioka, Yukinari Kato;
Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.
Cancer Med. 6:382-396(2017)